The orphan drug area is relatively new but fast growing. Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Michael Swit
Webinar sponsored by The Weinberg Group on Orphan Drugs, covering these topics:
The Basics of the Orphan Drug Act
Benefits of Orphan Drug status
Exclusivity
Protocol assistance, tax credits, and research grants
When is an indication is “rare”?
Orphan Drug Designation Requests – ensuring yours
robust and persuasive
Approval criteria for orphan products – how they
compare to non-orphan products
Challenges in the Orphan Drug Process
The orphan drug area is relatively new but fast growing. Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Michael Swit
Webinar sponsored by The Weinberg Group on Orphan Drugs, covering these topics:
The Basics of the Orphan Drug Act
Benefits of Orphan Drug status
Exclusivity
Protocol assistance, tax credits, and research grants
When is an indication is “rare”?
Orphan Drug Designation Requests – ensuring yours
robust and persuasive
Approval criteria for orphan products – how they
compare to non-orphan products
Challenges in the Orphan Drug Process
Regulatory requirements for orphan drugs delivery, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgavi/Belgaum, Karnataka, India.
KCR: Post-Authorisation Safety Studies (PASS) - Is the Ongoing Surveillance a...KCR
Post-Authorisation Safety Studies (PASS)
Is the Ongoing Surveillance a Blessing Or a Curse?
28th DIA EuroMeeting
7 April 2016, Hamburg, Germany
Magdalena Matusiak, MPharm
Manager, Clinical Development
Pharmacovigilance Team Lead, KCR
Method, tools and recommendations to boost Medical Science Liaisons Competence and performance.
Presentation of best practices to manage key opinion leaders
Marketing Strategy for a medical device companysaurabhmalani
This is a marketing strategy for a leading medical device company for a new product launch. This presentation won the Babson Marketing Case Competition - 2012 with prize money of $5000. 16 schools across the globe were competing in this competition.
Future Pharma Trends - Long-term opportunities tempered by short-term challengesscottosur
An overview of the key trends shaping the pharmaceutical industry today, and those that are set to play a central role in the future, as companies transition towards a new business model: Pharma 2.0.
Provides key strategies and trends shaping the future of the pharmaceutical industry. Examines the impact of the Obama administration on US healthcare, and the implications for Pharma. Assesses the implications of the current economic and financial situation on healthcare. Analyzes key growth drivers and resistors set to shape Pharma\'s future.
Contact me at sosur@datamonitor.com to learn more!
Regulatory requirements for orphan drugs delivery, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgavi/Belgaum, Karnataka, India.
KCR: Post-Authorisation Safety Studies (PASS) - Is the Ongoing Surveillance a...KCR
Post-Authorisation Safety Studies (PASS)
Is the Ongoing Surveillance a Blessing Or a Curse?
28th DIA EuroMeeting
7 April 2016, Hamburg, Germany
Magdalena Matusiak, MPharm
Manager, Clinical Development
Pharmacovigilance Team Lead, KCR
Method, tools and recommendations to boost Medical Science Liaisons Competence and performance.
Presentation of best practices to manage key opinion leaders
Marketing Strategy for a medical device companysaurabhmalani
This is a marketing strategy for a leading medical device company for a new product launch. This presentation won the Babson Marketing Case Competition - 2012 with prize money of $5000. 16 schools across the globe were competing in this competition.
Future Pharma Trends - Long-term opportunities tempered by short-term challengesscottosur
An overview of the key trends shaping the pharmaceutical industry today, and those that are set to play a central role in the future, as companies transition towards a new business model: Pharma 2.0.
Provides key strategies and trends shaping the future of the pharmaceutical industry. Examines the impact of the Obama administration on US healthcare, and the implications for Pharma. Assesses the implications of the current economic and financial situation on healthcare. Analyzes key growth drivers and resistors set to shape Pharma\'s future.
Contact me at sosur@datamonitor.com to learn more!
The biotech industry is characterised by constant change and fast-paced growth. Keeping up with the rapid evolution is close to impossible. Nevertheless, that’s exactly what Niels Guldager, Senior Technology Partner within biopharmaceuticals, does best. In this slide series, he presents the top ten biotech trends as he sees them.
Over 30 years after the Orphan Drug Act was passed, orphan drugs continue to be a lucrative market for pharma companies. Although orphan diseases affect small populations, these treatments address a high unmet need and also benefit from commercially attractive pricing structures and additional regulatory benefits.
Full graphic: http://www.isrreports.com/free-resources/5408/
Neglected and rare diseases traditionally have not been the focus of large pharmaceutical company research as biotech and academia have primarily been involved in drug discovery efforts for such diseases. This area certainly represents a new opportunity as the pharmaceutical industry investigates new markets. One approach to speed up drug discovery is to examine new uses for existing approved drugs; this is termed drug repositioning or drug repurposing and has become increasingly popular in recent years. Analysis of the literature reveals that using high-throughput screening there have been many examples of FDA approved drugs found to be active against additional targets that can be used to therapeutic advantage for repositioning for other diseases. To date there are far fewer such examples where in silico approaches have allowed for the derivation of new uses. It is suggested that with current technologies and databases of chemical compounds (drugs) and related data, as well as close integration with in vitro screening data, improved opportunities for drug repurposing will emerge. In this publication a review of the literature will highlight several proof of principle examples from areas such as finding new inhibitors for drug transporters with 3D pharmacophores and uncovering molecules active against Mycobacterium tuberculosis (Mtb) using Bayesian models of compound libraries. Research into neglected or rare/orphan diseases can likely benefit from in silico drug repositioning approaches and accelerate drug discovery for these diseases.
Consumer health: time for a regulatory re-think? is a report by RB in association with PAGB, written by the Economist Intelligence Unit. It looks at the changing healthcare environment and the role self-care plays and efforts at regulatory harmonisation, the barriers they have encountered, and prospects for the future.
IN THIS SUMMARY
The United States Food and Drug Administration (FDA) has significant reach in the American economy, ranging from medicines and medical devices to items on the grocery store shelves. Since its inception in 1906, the agency has faced a variety of technical and political challenges. Looking ahead, the FDA faces many new demands that could enlarge the agency’s already expansive mandate. New responsibilities may include the cost of medicine, consumers’ pursuit of perfection through drugs, consumer lifestyles, tobacco, and counterterrorism. As the nature of public health changes over time, it is inevitable that the FDA’s scope and responsibilities will change as well. In Inside the FDA, Fran Hawthorne explains the history of the FDA, how its processes work, and what the future may hold for this government agency.
SUBSCRIBE TODAY
http://www.bizsum.com/summaries/inside-fda
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...Bill Smith
Brand Acumen's Guide to Online International Non-Proprietary Name (INN) Electronic Name Submission Process.
Brand Acumen. The Global Leader in Pharmaceutical Name Development and Submission Strategy.
CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015Bill Smith
CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015.
Brand Acumen. The Global Leader in Pharmaceutical Name Development and Submission Strategy.
Accpac to QuickBooks Conversion Navigating the Transition with Online Account...PaulBryant58
This article provides a comprehensive guide on how to
effectively manage the convert Accpac to QuickBooks , with a particular focus on utilizing online accounting services to streamline the process.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Explore our most comprehensive guide on lookback analysis at SafePaaS, covering access governance and how it can transform modern ERP audits. Browse now!
Unveiling the Secrets How Does Generative AI Work.pdfSam H
At its core, generative artificial intelligence relies on the concept of generative models, which serve as engines that churn out entirely new data resembling their training data. It is like a sculptor who has studied so many forms found in nature and then uses this knowledge to create sculptures from his imagination that have never been seen before anywhere else. If taken to cyberspace, gans work almost the same way.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
"𝑩𝑬𝑮𝑼𝑵 𝑾𝑰𝑻𝑯 𝑻𝑱 𝑰𝑺 𝑯𝑨𝑳𝑭 𝑫𝑶𝑵𝑬"
𝐓𝐉 𝐂𝐨𝐦𝐬 (𝐓𝐉 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
𝐓𝐉 𝐂𝐨𝐦𝐬 provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
⭐ 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:
➢ 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
➢ SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
➢FreenBecky 1st Fan Meeting in Vietnam
➢CHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
➢ WOW K-Music Festival 2023
➢ Winner [CROSS] Tour in HCM
➢ Super Show 9 in HCM with Super Junior
➢ HCMC - Gyeongsangbuk-do Culture and Tourism Festival
➢ Korean Vietnam Partnership - Fair with LG
➢ Korean President visits Samsung Electronics R&D Center
➢ Vietnam Food Expo with Lotte Wellfood
"𝐄𝐯𝐞𝐫𝐲 𝐞𝐯𝐞𝐧𝐭 𝐢𝐬 𝐚 𝐬𝐭𝐨𝐫𝐲, 𝐚 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. 𝐖𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐫𝐭𝐥𝐲 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐢𝐞𝐬."
1. Top Trends in the
Orphan Drug
Industry
Your guide to the hot topics
influencing the industry now
2. Orphan Drug has become the most valuable designation in the Pharmaceutical
Industry. With each new rare disease focused on, the trends for the pharmaceutical
industry continue to shift towards a more personalized approach. The winds of change
are strong in Pharma – and that makes the trends that make up this movement even
more important. We gathered information from top pharmaceutical companies, patient
groups, regulatory agencies, and healthcare providers to find out what some of the top
trends were within the Orphan Drug movement. Varied in scope, these 17 trends are
where the industry is headed, and are a must-read for any company looking to enter
the rare disease marketplace.
3. The price of Orphan Drugs is increasingly under
scrutiny.
In the United States, The Department of Health and Human Services is fighting to keep
the price of Orphan Drugs discounted when they are not being used for their specific
rare disease designation, citing rule 340B. Meanwhile, industry claims that the same
rule means that all drugs as designated as Orphan by the FDA are free from discounted
pricing. A recent court ruling has put industry’s opinion in the right – but HHS hasn’t
backed down and continues to discount Orphan Drugs in certain cases. In the UK,
NICE and payers alike have begun to ask for more of a basis on pricing.
What is the 340B Drug Pricing Program?
1
4. Rare disease patient groups are forming registries.
Looked at as almost a status symbol by the more established
patient groups, these patient registries allow for a better
understanding of the natural history of many rare diseases. This is
essential for a more efficient development process, and industry
agrees. The fact that many patient organizations are embarking on
this form of data generation is good for the upstream development
of these drugs.
2
5. Breakthrough Therapy Drug Designation is a
boon for the orphan drug industry.
Breakthrough Therapies are defined by the FDA as a drug that, either alone or in
combination with another drug, treat a serious or life threatening disease and based on
preliminary clinical evidence may be far superior to anything in the market. For
Orphan Drugs, meeting those criteria are far easier that their standard counterpart.
Recently, Novartis gained a coveted third Breakthrough designation – meant for
treatment of a rare disease. Meanwhile, other companies, such as Pharmacyclics, have
cited the rule with chopping 7 to 9 months off the regulatory process.
3
6. Rare diseases are increasingly being seen as a tool
to cure the common ones.
Common diseases are often complex, consisting of many pathways
over several systems. Rare diseases, however, usually are far more
limited in their scope – often one gene and one pathway or
mechanism. In fact, many rare diseases account for subsets of
common ones. By studying rare diseases, there is a new thinking in
the field that we are in fact studying ways to cure the common ones
one pathway at a time.
4
7. Pressure is increasing for early access to potentially
lifesaving treatments via FDA Expanded Access and/or
Right to Try laws.
If someone’s prognosis is already fatal, are we justified in fast-tracking them a
proclaimed cure that could have deadly consequences in an attempt to save their life?
The government and industry seems to believe so – though in not so stark a situation.
While Expanded Access and Right to Try laws do not eliminate regulation, they
certainly help to bypass the bureaucracy when someone’s life could be saved by a risky
treatment.
5
8. Patient engagement in Clinical Trials is
increasing.
Both industry and the FDA have been increasingly growing
their desire to have patients actively involved in the clinical
trials process, both through patient representatives and
workshops aimed at educating the test candidates what,
exactly, it is they are looking for. The advent of patient groups
and registries is helping with this tremendously.
6
9. There is a shift toward more curative treatments like
gene therapy versus chronic, lifelong treatments.
Enabled by new technology, the days of taking a pill to live a normal life may be long
gone, and the days of an actual cure may be on the horizon. Gene therapies and other
treatments, such as CRISPR and RNAi, are proving to appear to live up to the hype.
These therapeutics have the potential to treat the disease – and never have to treat them
again.
7
10. Patient organizations are increasingly looking to
shape policies for rare diseases.
Patient groups have more and more influence, particularly as they form registries, and
they can put more pressure on the industry than previously thought – and they know
it. Patient groups have led to companies racing to develop therapies, developed
guidance on risk-benefit, and are increasingly looking to lobby for more favorable
terms to help patients in the long haul. See the AKU Society for a great example of a
patient organization working hard to push for what they need.
8
11. Policies continue to impact the rare disease space.
In 1982, nobody developed for orphan drugs. Starting with the passage of the Orphan
Drug Act in 1983, the rare disease space will always be tied to regulation and legislative
action due to the nature of the risk-benefit surrounding developing therapies for them.
In 2012, the Breakthrough Therapy laws changed the face of the game again, and future
laws will continue to shift the playing field in ways that we can’t even predict yet.
9
12. Governments are trying to further help companies
to work on rare diseases.
There are many means for governments to innovate to help spur growth in the rare
disease space, and adaptive licensing in Europe is just one example. As the impacts of
this research on the population as a whole increases, government interest will only
grow.
10
13. Rare disease is increasingly seen from a global
perspective.
Disease doesn’t end at our borders – and regulatory
agencies are starting to take note. The FDA and EMA are
working together more on rare disease topics than ever
before, and more countries are getting involved yearly.
This will help spur orphan drug laws in countries where
they do not currently exist.
11
14. Mergers will continue to be common.
Just recently, it was revealed that AbbVie was looking to acquire Shire for their Orphan
Drug focus – a merger that seems to be likely to take place. In an industry where one
breakthrough drug can make or break your finances, expect to see mergers and
acquisitions continue to be a major player in the marketplace, particularly as Big
Pharma knows they can purchase a smaller Orphan Drug pharmaceutical manufacturer
and limit their costs while reaping all of the rewards.
Find out more about the merger between AbbVie and Shire here >
12
15. Drugs will be increasingly produced via
Bioprocessing.
Biologics are becoming more and more common every day, and the advantages can’t be
ignored. The biologics space – and the cell culture field in general – is growing at a
staggering rate, and as more and more pharmaceuticals shift to biologics production, so
too will the orphan drugs.
13
16. Therapy areas are getting increasingly focused.
Long gone are the days where pharma companies decided to target
every single disease known to man. It is becoming more and more
common for companies to have therapeutic “areas of focus”,
specific diseases or areas that they are targeting for one strategic
reason or another. This increase in focus coupled with the intrinsic
advantage is driving an increase in Orphan Drug production, as
companies explore every aspect of their core competencies. For
example, if a company is focused on the rheumatics, rare disease
rheumatics are a natural extension.
14
17. R&D Centers and Innovation Clusters will spur
growth in the industry.
Countries are recognizing the benefit to catering to pharma and biotech companies –
and it is shown in the growth of R&D centers across the globe. This will help spur
orphan drug development and cooperation among typical competitors.
15
18. As new countries pass orphan drug legislation,
emerging markets will increasingly play a large role in
the industry.
The countries that currently have Orphan Drug legislation have spurred
unprecedented growth, but there are still several huge untapped markets – including
China – that will become an enormous boon to the industry as payers and patient
groups in those countries begin to push for the same rules as in the US or EU.
Attendance by regulators and payers from these countries at recent conferences, such
as the World Orphan Drug Congress, signals interest on the part of those countries in
expanding their legislation. This will open up a huge additional market for the already
booming orphan drug producers.
16
19. Big Data is helping speed up clinical trials and
promote faster access to information on all sides.
Big data is helping the entire biotechnology industry, and Orphan Drugs is no
exception. In fact, several big data and analysis companies attended last year’s World
Orphan Drug Congress. Being able to properly analyze data rapidly is speeding up
clinical trials as well as speeding up the opportunities to look into new challenges.
Likewise, the advent of patient registries is bringing forward new challenges to be
solved by Big Data as the field progresses.
17
20. Exploring all areas of rare disease- through strategic keynote presentation, focused
tracks, collaborative roundtable discussions and abundant 1-2-1 partnering; the
World Orphan Drug Congress gives you the opportunity to tailor your
participation and experience to your needs.
Taking place between April 24-25, 2015, the World Orphan Drug Congress remains the place to
discuss the hot topics currently being discussed within the industry.
Find out more at: www.terrapinn.com/orphandrugsus